Argenx Stock - H.C. Wainwright reiterates Buy rating
Published on 06/21/2026 at 13:44 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Edited by ad hoc news Analyst & Consensus Desk. Verified prior to publication on 06/21/2026, 11:30 UTC. Details in the imprint.
Argenx (NL0010832176) is back on analyst screens after a fresh call from H.C. Wainwright. The US broker reiterated its Buy rating and kept a $940 price target on the Nasdaq-listed biotech stock, according to a brief update referenced by Finanzen100.
All news and analysis on Argenx stock
Background, news and key figures on Argenx stock are bundled on the ad hoc news topic page and the company’s own investor-relations hub.
What H.C. Wainwright says
According to a German market overview that cites the note, H.C. Wainwright reaffirmed its positive view on Argenx with a Buy recommendation and a $940 price target on the shares, underscoring its constructive stance on the biotech’s pipeline and growth prospects.
The brief mention does not spell out detailed model changes, but the reiterated target implies upside versus recent Nasdaq levels, where Argenx last closed at $877.72 on 06/18/2026.
How analysts value Argenx
Argenx is widely covered by international brokerages as a mid-to-large cap biotech name. Consensus data from market portals show a predominantly positive stance, with most brokers rating the stock Buy or Outperform, alongside a smaller cluster of Hold recommendations that reflect valuation caution at current levels.
Against this backdrop, the Wainwright reiteration is consistent with the broader analyst picture rather than a sharp change of tone, but it helps keep the stock on institutional radar, especially as new clinical and commercial milestones approach.
The product behind the stock
Argenx generates the bulk of its revenue from Vyvgart, a drug targeting generalized myasthenia gravis and other autoimmune indications, and from its broader FcRn antibody pipeline. The company continues to invest heavily in R&D to expand label potential and geographic reach for these therapies.
Where the stock trades today
Argenx shares (NL0010832176) last closed on Nasdaq at $877.72 as of 06/18/2026, 16:00 ET.
Key facts on Argenx stock
- Company: argenx SE
- ISIN: NL0010832176
- WKN: A11602
- Ticker: ARGX
- Venue: Nasdaq
- Price (as of 06/18/2026, 16:00 ET): 877.72 USD
- Market cap: 55.19 billion USD (as of 06/18/2026)
- Sector / Industry: Health Care / Biotechnology
- Index membership: EURO STOXX 50
- Next earnings date: not officially scheduled
This article was AI-assisted and editorially reviewed. Price and company data without warranty; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Trading securities involves risk up to total loss of capital.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
